However, HER2 IHC is subject to assay and interobserver variability; so standardization and internal and external proficiency testing is an absolute prerequisite, especially because the IHC scoring system in gastric cancer is different from that of breast cancer. The gene discussed is ERBB2; the disease is breast cancer.